compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond
Company profile
Ticker
CMPX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Olivia Ventures, Inc.
SEC CIK
Corporate docs
Subsidiaries
Compass Therapeutics LLC • Compass Therapeutics Advisors Inc. • BBV International Compass Inc. • Biomatics – Compass, Inc. • CHI II Blocker LLC • OrbiMed Private Investments V – KA (Blocker), Inc. ...
CMPX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
21 Mar 24
8-K
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
21 Mar 24
8-K
Departure of Directors or Certain Officers
9 Jan 24
8-K
Compass Therapeutics Provides Corporate Update
5 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 30.43 mm | 30.43 mm | 30.43 mm | 30.43 mm | 30.43 mm | 30.43 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.98 mm | 3.99 mm | 1.97 mm | 3.24 mm |
Cash used (since last report) | n/a | n/a | 23.64 mm | 23.71 mm | 11.74 mm | 19.28 mm |
Cash remaining | n/a | n/a | 6.79 mm | 6.71 mm | 18.69 mm | 11.15 mm |
Runway (months of cash) | n/a | n/a | 1.7 | 1.7 | 9.5 | 3.4 |
Institutional ownership, Q3 2023
74.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 78 |
Opened positions | 8 |
Closed positions | 5 |
Increased positions | 30 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 176.37 bn |
Total shares | 101.91 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 22.36 mm | $44.05 bn |
Commander Aggregator | 7.79 mm | $31.15 mm |
JHG Janus Henderson | 6.66 mm | $13.09 bn |
Adage Capital Partners GP, L.L.C. | 6.38 mm | $12.57 bn |
BX Blackstone | 6.19 mm | $12.19 bn |
BLK Blackrock | 5.97 mm | $11.77 bn |
Braidwell | 5.95 mm | $11.73 bn |
Rock Springs Capital Management | 5.51 mm | $10.86 bn |
FMR | 4.55 mm | $8.97 bn |
Foresite Capital Fund V | 4.40 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | James P Boylan | Stock Option Common Stock | Grant | Acquire A | No | No | 1.96 | 40,000 | 78.40 k | 40,000 |
9 Feb 24 | Philip Ferneau | Stock Option Common Stock | Grant | Acquire A | No | No | 1.57 | 40,000 | 62.80 k | 40,000 |
9 Feb 24 | Ellen Chiniara | Stock Option Common Stock | Grant | Acquire A | No | No | 1.57 | 40,000 | 62.80 k | 40,000 |
8 Feb 24 | Schuetz Thomas J. | Common Stock | Payment of exercise | Dispose F | No | No | 1.45 | 44,782 | 64.93 k | 6,570,566 |
8 Feb 24 | Vered Bisker-Leib | Common Stock | Payment of exercise | Dispose F | No | No | 1.45 | 49,198 | 71.34 k | 3,124,426 |
News
Wedbush Reiterates Outperform on Compass Therapeutics, Maintains $8 Price Target
22 Mar 24
HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Maintains $10 Price Target
21 Mar 24
Compass Therapeutics Q4 EPS $(0.11) Misses $(0.09) Estimate
21 Mar 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
13 Mar 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
5 Mar 24